

From: [Nguyen, Janice](#)
To: [John Seibyl](#)
Subject: NRC Request for Additional Information for Molecular NeuroImaging, LLC (Mail Control Number 601213)
Date: Thursday, October 05, 2017 3:39:00 PM

Licensee: Molecular NeuroImaging, LLC
License No: 06-30624-01
Docket No: 030-35657
Control No: 601213

Dear Dr. Seibyl,

Could you please reply back to confirm receipt?

This is in response to Molecular NeuroImaging, LLC's amendment request dated September 26, 2017, requesting approval for an indirect transfer of control to Konica Minolta, Inc. In order to continue our review, please provide the following additional information:

1. Please indicate the date that the transaction will take place.
2. Please describe any planned change in members on the Board of Directors.
3. Describe the status of the licensee's facilities, including any known contamination and whether decontamination will occur prior to transfer. Since decommissioning is not anticipated at this current time, please describe any contamination and confirm that the transferee is knowledgeable of the extent and levels of contamination and applicable decommissioning requirements.
4. It is our understanding that operations will continue through the transfer process. If this understanding is correct, provide either an agreement to perform a survey confirming that the facility is free of contamination or an agreement by the transferee to accept the facility "as is" on the date of transfer.
5. Please describe the relationship between Molecular NeuroImaging, LLC and Konica Minolta, Inc. An organization chart showing the relationship would be helpful. In addition, indicate if Molecular NeuroImaging, LLC will retain the power to direct the actions with regard to licensed activities. If Konica Minolta, Inc. will be directing actions of licensed activities, please describe the process in detail. In addition, please indicate if any staff members from Konica Minolta, Inc. will be located within the currently licensed facility.
6. In order for the NRC to determine if this indirect change of control is to a "known entity," please indicate if Konica Minolta IC, Inc., Konica Minolta Precision Medicine, Inc., and/or Konica Minolta, Inc. possesses any NRC or Agreement State licenses. If so, please provide a copy.
7. Please provide the address, telephone number, and a contact person for Konica Minolta, Inc.

8. Please provide an organizational chart that clearly defines the relationship between Konica Minolta IC, Inc., Konica Minolta Precision Medicine, Inc., Konica Minolta, Inc., Invicro, LLC, and Molecular NeuroImaging, LLC.

The above information is taken from NUREG-1556, Volume 15, Revision 1, "Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Material Licenses." The notice of the proposed sale was posted to the NRC's website on October 2, 2017 and, per 10 CFR 2.1305, the public has 30 days to provide comments for the NRC's consideration. Therefore, the NRC would provide approval no earlier than November 1, 2017. If Molecular NeuroImaging, LLC's or Konica Minolta, Inc.'s representatives have questions, please feel free to contact me. The NRC is only concerned that control of the license and licensed activities and materials are not transferred prior to NRC's written approval. Any aspect of the sale that does not affect control of the license can, of course, proceed without NRC's approval.

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov<<http://www.nrc.gov>>; select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

The NRC's Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency's *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC's safety culture Web site at <http://www.nrc.gov/about-nrc/safety-culture.html>. We strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities."

You may respond to my attention in writing by letter, email (if letter is signed by senior management and scanned into a pdf format), or fax (610-337-5269), referencing mail control number 601213. If we do not receive a reply from you within 30 days, we will assume that you do not wish to pursue your application.

Thank you for your cooperation. Please feel free to contact me by telephone or e-mail if you have any questions.

Jan

Janice Nguyen
Senior Health Physicist
U.S. Nuclear Regulatory Commission
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406
Office (610) 337-5006
FAX (610) 337-5269